Home›Drug Pipeline› Icariin improves pain and cartilage scores in murine osteoarthritis, meta-analysis finds
Icariin improves pain and cartilage scores in murine osteoarthritis, meta-analysis findsIcariin Shows Potential to Reduce Osteoarthritis Pain in Mice
Frontiers in MedicinePublished August 24, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Interpret icariin's benefits as preclinical only; human efficacy remains unproven.
This is a meta-analysis of 13 preclinical studies involving 238 murine subjects, evaluating the effects of Epimedium-derived botanical metabolites, including icariin, in osteoarthritis models. The analysis synthesized outcomes across multiple inflammatory and pain-related markers.
Key findings include significant improvements in Pelletier scores (histological cartilage damage) and thermal paw withdrawal latency (a measure of pain sensitivity). The meta-analysis also reported decreases in serum IL-6, serum MMP-13, intra-articular IL-1β, IL-18, and MMP-1. For serum TNF-α, intra-articular MMP-13, and mechanical paw withdrawal threshold, the authors noted favorable pharmacological trends, but these were not stated as statistically significant.
The authors identified heterogeneity in intra-articular MMP-13 expression based on route of administration, which was a significant source of variability. Other limitations include the lack of reported effect sizes, confidence intervals, and p-values for most outcomes, limiting the precision of the findings.
Given the preclinical nature of the evidence, these results should be interpreted cautiously. They suggest potential pharmacological activity of icariin in murine osteoarthritis models, but do not imply clinical efficacy in humans. Further research, including well-designed human trials, is needed before any clinical recommendations can be made.
How this fits prior evidence
This meta-analysis extends prior coverage by providing a quantitative synthesis of icariin's effects in murine osteoarthritis, complementing earlier findings on genetic associations and mechanistic pathways. It aligns with the inflammaging and immunosenescence axis by showing reductions in inflammatory cytokines (IL-6, IL-1β, IL-18, TNF-α) and matrix-degrading enzymes (MMP-1, MMP-13). However, unlike the exosome trial that showed no superiority over placebo, this analysis suggests potential benefits, but the evidence is preclinical and not directly comparable. It addresses a gap by pooling data from 13 studies, yet the lack of human data limits its clinical relevance.
Researchers analyzed data from 13 different studies involving 238 mice to see how icariin affects osteoarthritis. This is a preclinical study, which means it was conducted on animals rather than humans. Because of this, the results do not prove that the treatment will work for people with joint pain.
The findings showed that icariin improved certain measures of joint health and reduced signs of inflammation in the mice. Specifically, researchers noted improvements in paw withdrawal times and scores related to joint condition. The study also found a decrease in several inflammatory markers and enzymes associated with tissue breakdown in the joints.
While these results are promising for future research, there are important reasons to be cautious. Some findings were only described as trends rather than certain results. Additionally, because this was done in mice, it is not yet known if icariin is safe or effective for human use. These findings represent early laboratory research and do not change current medical practices.
What this means for you:
Early animal studies show icariin may reduce joint inflammation, but more research is needed to see if it helps humans.
Common questions
Is icariin safe to use for human osteoarthritis?
Because this study was conducted on mice rather than humans, it is not known if icariin is safe or effective for people. You should always talk to your doctor before trying any new supplements or treatments for joint pain.
What did the study find regarding inflammation?
The study of 238 mice showed that icariin led to a decrease in several inflammatory markers, including IL-6 and TNF-alpha. It also showed a decrease in enzymes like MMP-1 and MMP-13 which are linked to joint issues.
How did the treatment affect pain in the mice?
The study reported that icaririn significantly improved Pelletier scores and thermal paw withdrawal latency. It also showed favorable pharmacological trends for mechanical paw withdrawal thresholds in the subjects.
BackgroundThe genus Epimedium (Berberidaceae) is widely used in traditional medicine. Recent studies indicate that its botanical metabolites (such as icariin) exhibit anti-inflammatory and chondroprotective potential in osteoarthritis (OA) models. However, a comprehensive analysis remains lacking.MethodsThis study was registered in PROSPERO (CRD420251143826). Chinese and English databases (PubMed, Web of Science, Embase, FMRS, VIP, CNKI, WanFang) were searched to collect preclinical controlled trials evaluating Epimedium extracts or their botanical metabolites for the treatment of OA in Murine subjects. The risk of bias was assessed using the SYRCLE tool, and data were synthesized using RevMan 5.4 and Stata 19.0.ResultsThirteen studies comprising 238 Murine subjects were included. Interventions utilizing Epimedium-derived botanical metabolites significantly improved Pelletier scores and thermal paw withdrawal latency (PWL). Concurrently, they decreased the levels of serum IL-6 and MMP-13, as well as intra-articular IL-1β, IL-18, and MMP-1. Favorable pharmacological trends were also observed for serum TNF-α, intra-articular MMP-13, and the mechanical paw withdrawal threshold (PWT). Subgroup analysis identified the route of administration as a significant source of heterogeneity for intra-articular MMP-13 expression.ConclusionBotanical metabolites derived from the genus Epimedium demonstrate pharmacological potential in Murine models of OA. The underlying mechanisms likely involve attenuating the production of systemic and local inflammatory factors and ameliorating cartilage damage.
